Luisa Crawford Jul 18, 2024 14:22
Injective (INJ)collaborates with 21Shares to launch AINJ, a new staking ETP offering INJ exposure and staking rewards via traditional finance venues.
Injective, a prominent player in the blockchain sector, has announced the launch of AINJ, the Injective (INJ)Staking Exchange-Traded Product (ETP) in collaboration with 21Shares. This innovative product will enable users to gain exposure to Injective's native token, INJ, through major traditional finance exchange venues and brokerages, while also capturing staking rewards, according to the Injective Blog.
Features and Benefits of AINJ
AINJ is positioned as a groundbreaking financial instrument designed to integrate the burgeoning world of decentralized finance (DeFi) with conventional financial systems. Investors can now access INJ without directly engaging with crypto exchanges, simplifying the investment process. Moreover, the staking mechanism embedded in the ETP allows users to earn additional rewards, thus providing dual benefits of asset appreciation and staking returns.
Strategic Collaboration with 21Shares
The partnership with 21Shares, a leading provider of cryptocurrency exchange-traded products, underscores Injective's commitment to expanding its market reach. 21Shares’ expertise in developing and managing ETPs ensures that AINJ will be a robust and attractive offering for both institutional and retail investors.
Injective Builder House Event
In addition to the AINJ launch, Injective is hosting the Injective Builder House event, which aims to unite core Injective developers, key industry partners, venture capitalists, and other stakeholders. This one-day event will provide an exclusive opportunity for participants to kickstart their builder journey on Injective, facilitating direct connections with core contributors, VCs, and liquidity providers.
These initiatives reflect Injective's broader strategy to foster a more integrated and user-friendly DeFi ecosystem. By bridging the gap between traditional finance and blockchain technology, Injective aims to attract a wider audience to its platform.
Image source: Shutterstock